German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay
Multidrug resistance is an emerging healthcare issue, especially concerning <i>Pseudomonas aeruginosa</i>. In this multicenter study, <i>P. aeruginosa</i> isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase produc...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/11/5/545 |
| _version_ | 1797502091257708544 |
|---|---|
| author | Jana Manzke Raphael Stauf Bernd Neumann Ernst Molitor Gunnar Hischebeth Michaela Simon Jonathan Jantsch Jürgen Rödel Sören L. Becker Alexander Halfmann Thomas A. Wichelhaus Michael Hogardt Annerose Serr Christina Hess Andreas F. Wendel Ekkehard Siegel Holger Rohde Stefan Zimmermann Jörg Steinmann |
| author_facet | Jana Manzke Raphael Stauf Bernd Neumann Ernst Molitor Gunnar Hischebeth Michaela Simon Jonathan Jantsch Jürgen Rödel Sören L. Becker Alexander Halfmann Thomas A. Wichelhaus Michael Hogardt Annerose Serr Christina Hess Andreas F. Wendel Ekkehard Siegel Holger Rohde Stefan Zimmermann Jörg Steinmann |
| author_sort | Jana Manzke |
| collection | DOAJ |
| description | Multidrug resistance is an emerging healthcare issue, especially concerning <i>Pseudomonas aeruginosa</i>. In this multicenter study, <i>P. aeruginosa</i> isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase production and susceptibility against ceftazidime-avibactam. Meropenem-resistant isolates of <i>P. aeruginosa</i> from various clinical materials were collected at 11 tertiary care hospitals in Germany from 2017–2019. Minimum inhibitory concentrations (MICs) were determined via microdilution plates (MICRONAUT-S) of ceftazidime-avibactam and meropenem at each center. Detection of the presence of carbapenemases was performed by PCR or immunochromatography. For meropenem-resistant isolates (<i>n</i> = 448), the MIC range of ceftazidime-avibactam was 0.25–128 mg/L, MIC<sub>90</sub> was 128 mg/L and MIC<sub>50</sub> was 16 mg/L. According to EUCAST clinical breakpoints, 213 of all meropenem-resistant <i>P. aeruginosa</i> isolates were categorized as susceptible (47.5%) to ceftazidime-avibactam. Metallo-β-lactamases (MBL) could be detected in 122 isolates (27.3%). The MIC range of ceftazidime-avibactam in MBL-positive isolates was 4–128 mg/L, MIC<sub>90</sub> was >128 mg/L and MIC<sub>50</sub> was 32 mg/L. There was strong variation in the prevalence of MBL-positive isolates among centers. Our in vitro results support ceftazidime-avibactam as a treatment option against infections caused by meropenem-resistant, MBL-negative <i>P. aeruginosa</i>. |
| first_indexed | 2024-03-10T03:27:56Z |
| format | Article |
| id | doaj.art-07ae7c0e3b5a438893651e394deb2d31 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T03:27:56Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-07ae7c0e3b5a438893651e394deb2d312023-11-23T09:47:33ZengMDPI AGAntibiotics2079-63822022-04-0111554510.3390/antibiotics11050545German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution AssayJana Manzke0Raphael Stauf1Bernd Neumann2Ernst Molitor3Gunnar Hischebeth4Michaela Simon5Jonathan Jantsch6Jürgen Rödel7Sören L. Becker8Alexander Halfmann9Thomas A. Wichelhaus10Michael Hogardt11Annerose Serr12Christina Hess13Andreas F. Wendel14Ekkehard Siegel15Holger Rohde16Stefan Zimmermann17Jörg Steinmann18Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, 90419 Nuremberg, GermanyInstitute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, 90419 Nuremberg, GermanyInstitute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, 90419 Nuremberg, GermanyInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, GermanyInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, GermanyInstitute of Clinical Microbiology and Hygiene, Regensburg University Hospital, 93053 Regensburg, GermanyInstitute of Clinical Microbiology and Hygiene, Regensburg University Hospital, 93053 Regensburg, GermanyInstitute of Medical Microbiology, Jena University Hospital, 07743 Jena, GermanyInstitute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, GermanyInstitute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, GermanyGerman National Consiliary Laboratory on Cystic Fibrosis Bacteriology, Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, GermanyGerman National Consiliary Laboratory on Cystic Fibrosis Bacteriology, Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, GermanyDepartment for Medical Microbiology and Hygiene, University Hospital Freiburg, 79106 Freiburg, GermanyDepartment for Medical Microbiology and Hygiene, University Hospital Freiburg, 79106 Freiburg, GermanyInstitute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, 51058 Cologne, GermanyInstitute for Medical Microbiology, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, GermanyInstitute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyDepartment of Infectious Diseases, University Hospital Heidelberg, 69120 Heidelberg, GermanyInstitute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, 90419 Nuremberg, GermanyMultidrug resistance is an emerging healthcare issue, especially concerning <i>Pseudomonas aeruginosa</i>. In this multicenter study, <i>P. aeruginosa</i> isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase production and susceptibility against ceftazidime-avibactam. Meropenem-resistant isolates of <i>P. aeruginosa</i> from various clinical materials were collected at 11 tertiary care hospitals in Germany from 2017–2019. Minimum inhibitory concentrations (MICs) were determined via microdilution plates (MICRONAUT-S) of ceftazidime-avibactam and meropenem at each center. Detection of the presence of carbapenemases was performed by PCR or immunochromatography. For meropenem-resistant isolates (<i>n</i> = 448), the MIC range of ceftazidime-avibactam was 0.25–128 mg/L, MIC<sub>90</sub> was 128 mg/L and MIC<sub>50</sub> was 16 mg/L. According to EUCAST clinical breakpoints, 213 of all meropenem-resistant <i>P. aeruginosa</i> isolates were categorized as susceptible (47.5%) to ceftazidime-avibactam. Metallo-β-lactamases (MBL) could be detected in 122 isolates (27.3%). The MIC range of ceftazidime-avibactam in MBL-positive isolates was 4–128 mg/L, MIC<sub>90</sub> was >128 mg/L and MIC<sub>50</sub> was 32 mg/L. There was strong variation in the prevalence of MBL-positive isolates among centers. Our in vitro results support ceftazidime-avibactam as a treatment option against infections caused by meropenem-resistant, MBL-negative <i>P. aeruginosa</i>.https://www.mdpi.com/2079-6382/11/5/545ceftazidime-avibactamsusceptibility testingcarbapenemases |
| spellingShingle | Jana Manzke Raphael Stauf Bernd Neumann Ernst Molitor Gunnar Hischebeth Michaela Simon Jonathan Jantsch Jürgen Rödel Sören L. Becker Alexander Halfmann Thomas A. Wichelhaus Michael Hogardt Annerose Serr Christina Hess Andreas F. Wendel Ekkehard Siegel Holger Rohde Stefan Zimmermann Jörg Steinmann German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay Antibiotics ceftazidime-avibactam susceptibility testing carbapenemases |
| title | German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay |
| title_full | German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay |
| title_fullStr | German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay |
| title_full_unstemmed | German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay |
| title_short | German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay |
| title_sort | german multicenter study analyzing antimicrobial activity of ceftazidime avibactam of clinical meropenem resistant i pseudomonas aeruginosa i isolates using a commercially available broth microdilution assay |
| topic | ceftazidime-avibactam susceptibility testing carbapenemases |
| url | https://www.mdpi.com/2079-6382/11/5/545 |
| work_keys_str_mv | AT janamanzke germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT raphaelstauf germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT berndneumann germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT ernstmolitor germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT gunnarhischebeth germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT michaelasimon germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT jonathanjantsch germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT jurgenrodel germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT sorenlbecker germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT alexanderhalfmann germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT thomasawichelhaus germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT michaelhogardt germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT anneroseserr germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT christinahess germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT andreasfwendel germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT ekkehardsiegel germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT holgerrohde germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT stefanzimmermann germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay AT jorgsteinmann germanmulticenterstudyanalyzingantimicrobialactivityofceftazidimeavibactamofclinicalmeropenemresistantipseudomonasaeruginosaiisolatesusingacommerciallyavailablebrothmicrodilutionassay |